1.12
0.00 (0.0%)
0.00 (0.0%)
Upgrade to Real-Time
Premarket
| Volume | 7,159 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
Level 1 Starter
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Caladrius Biosciences Inc | CLBS | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
 |
|
|---|---|---|---|---|
| 0.00 | 0.0% | 1.12 | 07:34:02 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.12 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 31 | 7,159 | - | 1.10 - 4.89 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 07:34:02 | 10 | $ 1.12 | USD |
Period:
Draw Mode:
Caladrius Biosciences Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 66.66M | 59.52M | 58.84M | $ - | $ - | -0.51 | -1.20 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | 1.40M | 15.20% |
Caladrius Biosciences News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CLBS Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.19 | 1.23 | 1.10 | 1.16 | 335,465 | -0.07 | -5.88% |
| 1 Month | 1.21 | 1.24 | 1.10 | 1.18 | 291,177 | -0.09 | -7.44% |
| 3 Months | 1.33 | 1.36 | 1.10 | 1.22 | 286,300 | -0.21 | -15.79% |
| 6 Months | 1.65 | 1.714 | 1.10 | 1.43 | 415,935 | -0.53 | -32.12% |
| 1 Year | 1.70 | 4.89 | 1.10 | 2.26 | 1,889,745 | -0.58 | -34.12% |
| 3 Years | 4.36 | 5.44 | 1.05 | 2.26 | 749,032 | -3.24 | -74.31% |
| 5 Years | 4.26 | 11.65 | 1.05 | 2.54 | 486,620 | -3.14 | -73.71% |
Caladrius Biosciences Description
| Caladrius Biosciences Inc is a clinical-stage biopharmaceutical company developing cellular therapies designed to reverse, not manage, disease. The company's product candidates include: CLBS119, for the repair of lung damage found in patients with severe COVID-19 infection who experienced respiratory failure, clinical trial to be initiated in 3Q2020 (USA); CLBS12, recipient of a SAKIGAKE (Japan) and ATMP (Europe) designations, eligible for early conditional approval for the treatment of critical limb ischemia based on an ongoing clinical trial (Japan); CLBS16, subject of the completed proof-of-concept ESCaPE-CMD clinical and planned Phase 2B (U.S.A.); and CLBS14, a Phase 3 ready clinical program in no option refractory disabling angina and recipient of a RMAT designation (USA). |
